CityAge: The Data Effect Vancouver

1. The Canadian Clinical
Trials Asset Map
(CCTAM)
Shurjeel H Choudhri, MD, FRCPC
Senior Vice President & Head, Bayer Inc
Alison Orth, BBA, CCRC
Project Management Consultant, BCCRIN

3. Global Patient Recruitment by Region

4. Clinical Trials by Country:
Percent Change from 2005 to 2010
Japan
160%
Percentage of Change
180%
China
140%
Russian Confederation
120%
Poland
100%
Australia
CANADA
80%
60%
Argentina
40%
Germany
20%
0%
-20%
2
3
4
5
6
7
8
9
1
10
11
France
12
13
14
15
16
Brazil
India
Country by Rank from 1 to 16

5. Clinical Trial Sites by Country:
Percent Change from 2005 to 2010
250%
Japan
Percentage of Change
200%
India
China
150%
Russian Confederation
Argentina
100%
Poland
CANADA
50%
Brazil
Australia
South Africa
0%
1
2
3
4
5
6
7
8
9
-50%
10
11
United Kingdom
12
13
14
15
16
Spain
France
Country by Rank 1 to 16

6. Health Canada CTAs
CTA = Clinical Trial Applications

7. Clinical Trial Density & Growth
Rate
Nature Biotechnology January 2012

8. Initiatives in the US
TransCelerate BioPharma Initiative
DrugDev.org

9. Canada’s Strengths in Clinical
Trials
•
•
•
•
•
•
•
High reputation of researchers, organizations & outputs
Diverse population
Disease & population-specific networks & health charities
National progress on operational barriers
Interested public
Publically-funded healthcare & provincial funding for health
Federal & provincial leadership

10. Clinical Trials Summit 2011
• The first ever clinical trial steering committee meeting (Sep 2011)
• 150 experts from Government, Academia, Clinical Sites & Industry
• Topics critical to the Canadian clinical trial environment:
•
•
•
•
•
Ethics review process
Recruitment, patient retention & follow-up (administrative databases, e-records)
Cost structure
Administrative (contracts, standard operating procedures, education, training)
Future – what strengths can Canada develop that would make a difference in 5-10
years?

11. Clinical Trials Action Plan
http://www.acaho.org/?policy_2012
http://www.canadapharma.org/en/our-industry/clinical-trial-

12. Clinical Trials Action Plan
Vision: Canada to become a premier country globally for
conducting industry led clinical trials (CT)
Strategic Goals:
1. Establish short & longer term implementation capacity for this action
plan & coordination of other CT improvement activities
2. Improve business operations through better cost, quality, & speed of
clinical trial start-up times
3. Shape a positive future business environment & signal Canada’s interest
globally with information & incentives

13. What is Canadian Clinical Trials Asset
Map (CCTAM)?
 Component of Strategic Goal # 3 of Action Plan
 Web-based “living”, easily searchable, interactive
database of Canadian clinical research capabilities
 Broad umbrella of stakeholders including Rx&D &
member companies, CIHR, DFAIT, Health Canada,
Industry Canada, ACAHO, BCCRIN, CTO, N2 and
independent research centers

14. CCTAM
Objectives
 Improve capacity for both the academic &
commercial sectors to conduct clinical studies in
Canada
 Position Canada globally as an attractive destination
for clinical trial investments

15. CCTAM: Design Principles
• Consider from view of both end user’s & the sites
• Ensure it meets evolving stakeholder
requirements
• Optimize scope & application of the tool
• Leverage & integrate experiences from existing
asset maps where possible to avoid duplication
of effort

16. Features of CCTAM
 Bilingual
 Comprehensive data set
 Regular updates
 Easy to search
 No cost to contributors to use

17. Who Stands to Benefit?
 Academic Research Sites
 Independent Research Sites
 Government
 Industry
 Academia
 Canadians

18. Progress to Date
 Key audiences & stakeholders identified & engaged
 Existing asset maps audited to identify unmet needs &
potential data sources
 British Columbia Clinical Research Infrastructure
Network’s (BCCRIN) Asset Map (http://
assets.bccrin.ca/ is being considered as a base
framework for CCTAM
 Initial data points to be included identified

19. Progress to Date contd.
 Work underway to enhance existing BCCRIN asset
map
 Agreement in principle across RX&D member
companies to contribute data
 Part I of communication strategy developed

20.
Changing
the
landscape
for
clinical
research
in
BC.
www.bccrin.ca

21. A
collabora7ve
partnership
of
provincial
health
authori7es,
universi7es,
industry
associa7ons
and
funding
agencies.
Focused
on
transforming
the
clinical
research
landscape
in
BC.
A@ract
increased
investment
into
BC;
provide
improved
access
to
innova7ve
medicines
and
diagnos7cs.
Develop
first
in
class
research
processes
and
infrastructure
to
support
clinical
research
personnel
and
ac7vi7es.
This
network
has
the
poten7al
to
profoundly
alter
the
clinical
landscape
in
Canada
and
become
a
gold
standard
center
for
clinical
research
worldwide.
www.bccrin.ca

22. www.bccrin.ca

23.  Online, searchable database with interactive elements
 Information on clinical trials investigators, sites, research units, ethics
boards in BC
 Captures BC biomedical, clinical, health services policy, population and
public health and medical device researchers
 Includes academic, institutional and community/independent sites from
across the province
 Industry standard: PHP, MySQL, Javascript. Allows for future updates
and extensions
www.bccrin.ca/
www.bccrin.ca

24. Summary
 CCTAM initiative only possible due to the extraordinary
participation & commitment of groups & individuals across
industries, sectors & geographical locations in Canada
 Significant progress over the past 18 months in developing the
CCTAM
 Once complete, CCTAM will be a comprehensive one-stop tool for
both local & global entities considering Canada as a site for
clinical research
 CCTAM will continue to evolve & develop true to its living tool
concept

25. For more information…
Please email:
cctam@canadapharma.org

26.
Thanks!
Questions?
You can tell whether a man is clever by his
answers.
You can tell whether a man is wise by his
questions.
Naguib Mahfouz